Pfizer is presenting its progress in developing new approaches to oncology care and its cancer drugs at the American Society of Clinical Oncology (ASCO®) 2024 Annual Meeting, to be held May 31 to June 4 in Chicago.
More than 50 abstracts, including 11 oral presentations, will be presented from Pfizer's portfolio of approved and pipeline therapies in the company's major tumor areas and scientific modalities, including small molecules, antibody-drug conjugates (ADCs) and bispecific antibodies.
'We are delighted to participate in our first annual ASCO meeting following the creation of Pfizer's new oncology organization, where we will highlight our efforts to accelerate the development of breakthrough medicines that help people with cancer live better, longer lives,' said Chris Boshoff, Chief Oncology Officer and Executive Vice President of Pfizer.
'We look forward to key data presentations from our newly developed portfolio, including additional evidence reinforcing the benefit of several approved drugs and promising new data from our large and diverse pipeline.'
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows:
- primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.;
- specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.;
- oncology products (12.1%);
- other (1.3%).
At the end of 2022, the group had more than 35 manufacturing sites worldwide.
Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
PFIZER, INC. 
